Connect with us

Technology

Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis

Published

on

NASHVILLE, June 28, 2023 /PRNewswire/ — Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. This milestone marks a significant step forward in the development of advanced treatment options for individuals affected by this chronic and debilitating skin condition.

The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of safety.

Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1). Despite the availability of various treatment options, there remains an unmet need for more effective and safer therapies. With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis.

The Phase 2b clinical trial will continue to build upon a recent trial that has evaluated the safety and efficacy of AMTX-100 CF3 in a larger cohort of adult patients that has shown favorable efficacy bypassing the need for rescue steroid treatment. This randomized, double-blind, placebo-controlled study will be conducted at 8-10 clinical sites across the country. This study is seeking 60 participants to generate a 1:1 ratio between placebo and active arms of the study. The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of treatment safety.

This clinical trial will include a 28-day treatment period with twice daily treatment and a 2-week follow-up assessment post-treatment to determine therapeutic efficacy. In addition, participants will receive a topical emollient 2-weeks prior to trial to exclude participants who may be impacted by a placebo effect. Precision medicine techniques will also be used to assess changes in the expression of genes involved in inflammation.

“We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3,” said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. “At Amytrx, we are committed to developing innovative therapies that can make a meaningful difference in the lives of patients. This trial represents a crucial step towards bringing a safe and targeted treatment option to adults suffering from atopic dermatitis, in addition to other chronic inflammatory skin diseases such as psoriasis, vitiligo, lupus, graft vs. host, and more.”

Amytrx Therapeutics has invested years of research and development into the creation of AMTX-100 CF3. This unique topical formulation of their anti-inflammatory peptide has shown promising results in preclinical and clinical studies. AMTX-100 CF3 utilizes a novel untapped intracellular target to control inflammation. The company believes that AMTX-100 CF3 has the potential to provide durable relief, enhance quality of life, and minimize the burden of this chronic condition with a revolutionary approach that interacts with a key checkpoint in the initiation of inflammation.

The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway. Eligible adults interested in participating or learning more about the trial are encouraged to visit the ClinicalTrials.Gov listing # NCT04313400 or visit Amytrx Therapeutics’ website at www.amytrx.com. The company welcomes collaboration with research institutions that wish to contribute to advancing the knowledge and treatment of other inflammatory skin disorders.

The current topical formulation of AMTX-100 CF3 being studied in the Phase 2b clinical trial provides an example of the various formulations available for novel anti-inflammatory peptide AMTX-100. Amytrx Therapeutics is actively exploring other delivery methods to cater to the diverse needs of patients across a variety of inflammatory diseases. These formulations include oral, injectable, nasal spray, and other options. This comprehensive approach underscores Amytrx Therapeutics’ commitment to developing a range of therapeutic options that can effectively target inflammation and provide additional treatment strategies.

About Amytrx Therapeutics

Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world’s most debilitating diseases. For further information, please visit www.amytrx.com

Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 52. https://doi.org/10.1186/s13223-018-0281-6

View original content to download multimedia:https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

SOURCE Amytrx Therapeutics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Aprecomm Upends the CX Industry with Appointment of Philippe Alcaras to its Advisory Board

Published

on

By

Industry leader Philippe Alcaras, former CEO of Airties, has joined Aprecomm as an advisor, bringing unparalleled knowledge and experience to guide its leadership team.

BANGALORE, India, April 28, 2025 /PRNewswire/ — Today, Aprecomm, the intuitive network and customer experience platform provider, announced a major coup by appointing former Airties CEO and highly experienced telecom leader Philippe Alcaras as an advisor. Presiding over Airties during a time of substantial growth, when the company expanded its footprint into new markets, Philippe brings the experience and business acumen necessary to support and advise Aprecomm’s Executive Team as global demand for its AI-driven customer experience (CX) platform continues to grow at pace.

“Aprecomm has already secured over 20% of the Indian fixed broadband market and is supplying close to 50 service providers with its customer experience optimization software,” said Philippe Alcaras, Aprecomm’s latest advisor. “With the penetration of managed WiFi estimated at only 15-30% globally [1], Aprecomm has a huge opportunity to disrupt the market with its AI data-driven approach and fast speed to market—I’m excited to join Pramod and his Team and support this high-growth phase.”

Among several key focus areas, Philippe will bring extensive experience to help guide the company’s positioning and narrative for investor outreach and fundraising initiatives, support engagement with strategic customers and partnerships, ⁠and provide ongoing input and feedback on corporate governance, product strategy, and roadmap development.

“I’m thrilled to welcome Philippe, who will provide his expertise and advice to the Company during our next growth phase,” said Pramod Gummaraj, Founder & CEO, Aprecomm. “Philippe’s knowledge will be invaluable as we continue to disrupt the industry, helping service providers harness AI’s power to serve their subscribers better, bringing joy to online experiences while achieving significant operational savings through our intuitive and self-healing approach to network management.”

Serving both residential and business subscribers, Aprecomm’s CX suite helps broadband service providers (BSPs) transform their connectivity approaches. By utilizing sophisticated artificial intelligence, including a unique quality of experience algorithm, Aprecomm is paving the way for intuitive zero-touch networks. Aprecomm adopts a self-optimizing and self-healing approach to managed WiFi, adjusting the network to accommodate the unique needs of each user and the application they are using. Aprecomm’s advanced analytics and automated support tools provide access to real-time data, enabling service providers to monitor end-to-end network performance. Its CX suite is field-proven [2] for enhancing subscriber satisfaction and reducing operational costs.

About Philippe Alcaras
Based in Dubai (UAE), Philippe Alcaras holds non-executive positions as Chairman of OnRobot (Odense, Denmark), Chair of the Advisory Board at Vianeos (Paris, Dubai), and Board Member at S3 Connected Health (Dublin). From 2012 to 2022, Philippe was the CEO of Airties, leading the company to become a global leader in home network WiFi performance. He also served as the General Manager of Philips Home Networks, CEO of Nagra France, and General Manager of Digital TV Devices at Vantiva. Philippe graduated with an MBA from KEDGE (Marseille) and is certified as an INSEAD International Director.

Aprecomm harnesses the power of AI to provide a unique applications suite that enables service providers to create self-optimizing and self-healing broadband networks.

Our quality-of-experience engine monitors and optimizes WiFi performance to ensure consumers enjoy the best possible internet experience. At the same time, our cloud-based support applications leverage real-time data to predict and resolve customer service issues before they happen, saving providers time and money.

Aprecomm manages over 7 million home and business locations, partnering with more than 45 service providers worldwide.

We’re making intuitive, self-healing networks a reality.

Follow Aprecomm on LinkedIn here.

#IntuitiveNetworks
#BringingJoyToOnline

Visit www.aprecomm.ai to discover more.

Press contact:

corporatecomms@aprecomm.ai

[1] Various industry estimates
[2] Excitel case study

Photo: https://mma.prnewswire.com/media/2672543/Aprecomm_Philippe_Alcaras.jpg
Logo:  https://mma.prnewswire.com/media/2672542/Aprecomm_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aprecomm-upends-the-cx-industry-with-appointment-of-philippe-alcaras-to-its-advisory-board-302437529.html

SOURCE Aprecomm

Continue Reading

Technology

Centric PLM for Food & Beverage and Grocery Tackle Tariffs Head-On

Published

on

By

Real-time data, cost simulation and supplier management are all strategies employed by Centric PLM to combat tariff uncertainty

CAMPBELL, Calif., April 28, 2025 /PRNewswire-PRWeb/ — Centric Software provides the most innovative enterprise solutions to plan, formulate, develop, procure, manufacture and sell consumer goods products in food & beverage, grocery, fashion and multi-category retail to achieve strategic and operational digital transformation goals.

With the recent burst of tariff activity, food & beverage companies and grocery retailers are faced with widely fluctuating ingredient costs. Changes in regulations are happening day-by-day and consumer response is also factoring into sales, so there is no time for consultation and lengthy analyses; response to tariffs must be reactive and swift.

Real-time access to data becomes crucial in today’s circumstances. A modern PLM solution has modules that can facilitate agile product development, enabling companies to quickly adapt to market changes. By streamlining collaboration and workflow processes, food & beverage and grocery companies can revamp their offerings or develop new products that cater to evolving consumer demands and benefit from AI-functionalities like least cost formulation to protect margins. Agility is necessary for maintaining market relevance amid shifting market conditions.

With Centric PLM, companies can evaluate and compare suppliers, simulate costing scenarios, adjust landed cost calculations, support multi-sourcing strategies and facilitate quick supplier revision requests. With AI formula matching, developers get a head start in formulating the next new product. Centric PLM also manages packaging: from briefs, to specifications to artwork and labeling. Ingredient and nutrition label information is pulled directly from PLM into packaging, eliminating the chance for error when transferring data manually between systems.

To improve consumer experience across all touchpoints, Centric PXMTM, Centric product experience management, combines product information management (PIM), digital asset management (DAM), content syndication to e-comm sites, marketplaces and social media and digital shelf analytics (DSA). It captures demand signals from digital sales channels and shows consumer behavior in real-time, creating a continuous feedback loop, so brands can quickly adjust products, pricing and inventory to personalize customer experiences and increase sell-through in response to whatever the current conditions are.

Traditional ways of managing tariffs, often siloed within finance or sourcing teams no longer provide the visibility or speed businesses need to stay competitive. Navigating tariffs involves more than understanding costs; it also requires compliance with evolving international trade regulations. Non-compliance can lead to penalties and operational disruptions. Being aware of the latest regulatory changes through a comprehensive tech platform is key. Centric PLM integrates with regulatory databases like USDA FoodData Central, SR Legacy and CIQUAL. A partnership with the global regulatory and food safety service provider FoodChain ID, provides users with access to 220 global regulatory libraries.

“Completely market-driven, the breadth of Centric Software’s AI-powered technology solutions covers the end-to-end product lifecycle,” says Chris Groves, CEO of Centric Software. “Centric solutions, including PLM and PXM, provide robustness to food companies whose ingredients often hail from all corners of the globe. During times of economic volatility, Centric solutions equip food & beverage producers and retailers, including grocery which is often a diverse range of consumer goods products, to better handle market and supply chain disruptions.”

Learn how to mitigate retail uncertainty with Centric’s Tariff Hub

Request a demo 

Media Contact

Celia Newhouse, Centric Software, +14385015498, cnewhouse@centricsoftware.com, www.centricsoftware.com

View original content to download multimedia:https://www.prweb.com/releases/centric-plm-for-food–beverage-and-grocery-tackle-tariffs-head-on-302440562.html

SOURCE Centric Software

Continue Reading

Technology

Innodisk Paves the Way for Next-Gen Data Centers with its First PCIe Gen5 SSD Series

Published

on

By

TAIPEI, April 29, 2025 /PRNewswire/ — Innodisk, a leading industrial-grade flash storage provider, announces the launch of its latest PCIe Gen5 SSD series, designed to meet the OCP Data Center NVMe SSD spec v2.0 and the increasing demands of AI model training, big data analytics, and data-intensive environments.  

The new series supports multiple form factors, including U.2, as well as EDSFF E1.S, E3.S, and the brand-new E3.L for data center applications, catering to the diverse needs of enterprise and data center environments. This marks a new chapter for Innodisk in further fulfilling enterprise demands.

The Innodisk PCIe Gen5 SSD, built with the latest PCIe Gen 5 x4 interface and NVMe 2.0 protocol, overcomes the speed and latency limitations of traditional storage interfaces. With up to 128TB of high-density NAND storage, it delivers speeds of up to 14GB/s (read) and 10GB/s (write), enabling lightning-fast data transfers for data-intensive applications.

Enterprise data centers managing large-scale storage deployments and multi-tiered environments often require out-of-band and batch management capabilities, which present growing challenges. Innodisk PCIe Gen5 SSD addresses these demands with NVMe-MI for streamlined SSD management and multi-namespace support, ensuring scalable and efficient storage operations.

To ensure high quality and alignment with market trends, the PCIe Gen5 SSD aims to enhance integration with industry-leading data center standards, such as OCP Data Center NVMe SSD spec v2.0. Additionally, it is intended to be built for seamless integration with VMware, optimizing compatibility with virtualized environments and overall system performance.

Innodisk’s PCIe Gen5 SSD also features advanced security mechanisms, ensuring robust data protection and seamless integration. Secure Boot technology authenticates digital signatures during firmware updates, preventing unauthorized modifications and ensuring that only trusted firmware is executed.  

Other than that, Innodisk offers exceptional extensive firmware compatibility and customizable solutions, ensuring seamless integration into diverse enterprise environments.  

The Innodisk PCIe Gen5 SSD will be available starting Q2 2025. For more information, please visit www.innodisk.com.

Photo – https://mma.prnewswire.com/media/2674649/Press_Photo_PCIe_Gen5_Series.jpg

View original content:https://www.prnewswire.co.uk/news-releases/innodisk-paves-the-way-for-next-gen-data-centers-with-its-first-pcie-gen5-ssd-series-302439762.html

Continue Reading

Trending